Home โ€บ Gut & Digestion โ€บ Clinical Trial
Clinical Trial ยท PHASE3 ยท Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn’s Disease

14 October 2026 NCT07577843 ClinicalTrials.gov โ†—
✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE3
Participants
ALL
Age Range
18 Years+

About This Trial

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive [worsens with time] and life-threatening disease of the intestine).

Who Can Join?

Inclusion criteria: * Have a diagnosis of Crohn's disease (CD) or fistulizing CD established greater than or equal to (>=) 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD * Have moderately to severely active CD based on crohn's disease activity index (CDAI) criteria defined as a baseline CDAI score >= 220 but less than or equal to (= 4.0, based on the unweighted CDAI component of the number of liquid or very soft stools or b. Mean daily AP score >= 2.0, based on the unweighted CDAI component of abdominal pain (AP) * Have moderately to severely active ileal and/or colonic CD as assessed by central review of the screening video ileocolonoscopy based on simple endoscopic score for crohn's disease (SES-CD) criteria * Have had an inadequate initial response, loss of response, or intolerance to previously approved systemic therapies Exclusion…

⚠ Always speak to your doctor before applying to any clinical trial.

Clinical trials can speed up access to new treatments

Joining a trial may give you access to cutting-edge therapies before they're widely available on the NHS — while helping advance medical research.

More Gut & Digestion Trials

Free health updates

Stay one step ahead
of your condition.

New trial alerts, treatment news, and plain-English updates โ€” matched to your condition. Free forever.

No spam. Unsubscribe anytime. Your data is private.